KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eli Lilly (LLY) EBT (2016 - 2025)

Eli Lilly (LLY) has disclosed EBT for 17 consecutive years, with $8.3 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT rose 64.07% year-over-year to $8.3 billion, compared with a TTM value of $25.7 billion through Dec 2025, up 102.93%, and an annual FY2025 reading of $25.7 billion, up 102.93% over the prior year.
  • EBT was $8.3 billion for Q4 2025 at Eli Lilly, up from $7.2 billion in the prior quarter.
  • Across five years, EBT topped out at $8.3 billion in Q4 2025 and bottomed at $427.2 million in Q3 2023.
  • Average EBT over 5 years is $2.9 billion, with a median of $2.1 billion recorded in 2022.
  • The sharpest move saw EBT crashed 72.71% in 2023, then soared 355.32% in 2025.
  • Year by year, EBT stood at $1.8 billion in 2021, then grew by 13.94% to $2.1 billion in 2022, then increased by 19.64% to $2.5 billion in 2023, then skyrocketed by 100.87% to $5.0 billion in 2024, then skyrocketed by 64.07% to $8.3 billion in 2025.
  • Business Quant data shows EBT for LLY at $8.3 billion in Q4 2025, $7.2 billion in Q3 2025, and $6.8 billion in Q2 2025.